AGIO:NSD-Agios Pharm (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 34.37

Change

+0.18 (+0.53)%

Market Cap

USD 3.52B

Volume

0.66M

Analyst Target

USD 65.45
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.47 (+0.61%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+2.21 (+0.31%)

USD 84.94B
ARGX argenx NV ADR

+2.05 (+0.33%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-0.75 (-0.31%)

USD 31.66B
BGNE BeiGene Ltd

+3.06 (+1.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+3.23 (+0.90%)

USD 16.18B
MRNA Moderna Inc

+0.16 (+0.40%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.17 (+0.67%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.28 (+1.47%)

USD 13.67B
INCY Incyte Corporation

-0.35 (-0.50%)

USD 13.52B

ETFs Containing AGIO

WDNA WisdomTree BioRevolution .. 2.95 % 0.00 %

-0.04 (-0.30%)

USD 2.41M
WRNA:XETRA WisdomTree BioRevolution .. 2.95 % 0.00 %

N/A

USD 2.77M
WBIO:LSE WisdomTree BioRevolution .. 2.92 % 0.00 %

N/A

USD 4.00M
WDNA:LSE WisdomTree BioRevolution .. 2.44 % 0.00 %

N/A

N/A
AVSC American Century ETF Trus.. 0.38 % 0.00 %

+0.58 (+-0.30%)

USD 1.52B
EES WisdomTree U.S. SmallCap .. 0.00 % 0.38 %

+0.32 (+-0.30%)

USD 0.65B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 54.33% 84% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.33% 84% B 86% B+
Trailing 12 Months  
Capital Gain 50.81% 83% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.81% 83% B 86% B+
Trailing 5 Years  
Capital Gain -29.10% 68% D+ 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.10% 67% D+ 32% F
Average Annual (5 Year Horizon)  
Capital Gain 5.09% 54% F 53% F
Dividend Return 5.09% 54% F 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.53% 68% D+ 42% F
Risk Adjusted Return 11.17% 59% D- 42% F
Market Capitalization 3.52B 92% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector